The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $202.83

Today's change-1.13 -0.55%
Updated March 6 9:46 AM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $202.83

Today's change-1.13 -0.55%
Updated March 6 9:46 AM EST. Delayed by at least 15 minutes.

Reversal following new 52-week high

Valeant Pharmaceuticals International Inc is lower today, dropping (U.S.)$1.13 or 0.55% to (U.S.)$202.83 after setting a new 52-week high. Over the last five days, shares have gained 2.71% and are currently 1.08% off of the 52-week high. Shares have outperformed the S&P 500 by 34.85% during the last year.

Key company metrics

  • Open(U.S.) $203.31
  • Previous close(U.S.) $203.95
  • High(U.S.) $204.17
  • Low(U.S.) $202.60
  • Bid / Ask(U.S.) $202.82 / (U.S.) $203.00
  • YTD % change+41.73%
  • Volume456,051
  • Average volume (10-day)7,315,625
  • Average volume (1-month)4,200,551
  • Average volume (3-month)2,779,142
  • 52-week range(U.S.) $106.00 to (U.S.) $205.04
  • Beta0.90
  • Trailing P/E75.89×
  • P/E 1 year forward19.50×
  • Forward PEG0.65×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.67
Updated March 6 9:46 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.04%

Based on its net profit margin of 11.04%, Valeant Pharmaceuticals International Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue2,2802,0562,0411,886
Total other revenue--------
Total revenue2,2802,0562,0411,886
Gross profit1,6901,4951,4561,368
Total cost of revenue590561586518
Total operating expense1,6721,3721,6861,623
Selling / general / administrative525504516482
Research & development59596761
Depreciation / amortization437393366355
Interest expense (income), net operating--------
Unusual expense (income)5587153250
Other operating expenses, total7-2320-43
Operating income608684355263
Interest income (expense), net non-operating-224-258-241-247
Gain (loss) on sale of assets--------
Other--------
Income before tax5903771215
Income after tax534276122-20
Income tax, total56100-125
Net income535275126-23
Total adjustments to net income--------
Net income before extra. items535275126-23
Minority interest1-14-2
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items535275126-23
Inc. avail. to common incl. extra. items535275126-23
Diluted net income535275126-23
Dilution adjustment--------
Diluted weighted average shares342341341335
Diluted EPS excluding extraordinary itemsvalue per share1.560.810.37-0.07
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.711.010.670.43